3 Long-term Income Plays: Legal And General Group Plc, GlaxoSmithKline Plc And SSE PLC

Legal & General Group Plc (LON: LGEN), GlaxoSmithKline Plc (LON: GSK) and SSE PLC (LON: SSE) will bring joy to long-term income seekers, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Share price growth can give investors a real buzz in the short-term, but it’s the dividend income that brings the most satisfying long-term rewards. If you can generate 4% or 5% a year and use that to buy more shares in the same company, eventually you will be talking real money.

Up to three-quarters of your long-term returns will come from dividend income. The key phrase here is long-term. Here are three income stocks with staying power.

Legal & General Group

Over the last five years, FTSE-listed insurance giant Legal & General Group (LSE: LGEN) has doubled your money in share price growth alone. The last year has been stickier with the stock down 15%, but that won’t worry long-term income seekers, as L&G currently yields 5.62%. In fact, it works in their favour, because if they re-invest their dividends they’ll pick up more stock at the lower price.

Somebody who invested five years ago, when the stock traded at 116p (against 238p today), is effectively getting a yield of 11.5% on their original investment. FTSE insurers have all been hit by wider stock market uncertainty yet L&G still has plenty in its favour, as a major presence in three fast-growing areas: low-cost tracker funds, UK workplace auto-enrolment schemes and bulk annuities. Earnings per share (EPS) are forecast to rise 7% this year and 8% in 2016, when the yield is expected to hit an even juicier 6.4%.

GlaxoSmithKline

Investment fashions change but one thing seems eternal: pharmaceutical giant GlaxoSmithKline (LON: GSK) is still the FTSE 100 poster boy for dividend income. Yet even dividend heroes can suffer their moments of misfortune, with the Chinese bribery scandal and more importantly, fears of a patent cliff, hitting investor sentiment. Glaxo has been trying to wean itself off its dependence on respiratory treatment Advair/Seretide, with sales down sharply on generic competition. Moves to diversify into vaccines and consumer health, pharmaceutical products and the HIV franchise, are finally bearing fruit.

Four years of negative EPS are expected to turn positive with a vengeance in 2016, rising 14%. Forecast dividend growth looks less spectacular, but the yield is expected to continue hovering around 5.4%, perfect for investors who like to play the long game.

SSE

Some may think I’m rash by including utility company SSE (LSE: SSE) under the heading “long-term income plays”. Its dividend may yield a juicy 5.83% but there has been talk of a cut as cover gets stretched. SSE has been hit by falling energy prices and increased retail market competition, as disgruntled customers switch from the Big Six energy companies to smaller challengers.

Management has committed to raising its dividend by RPI inflation at least, a commitment it stands by even though EPS are expected to fall from 124.1p in the year to March 2015 to 111.79p this year, a drop of almost 10%. It also warned that dividend cover could range from around 1.2 times to around 1.4 times over the next three years, but the yield is still forecast to hit 6% by March 2018, suggesting fears of a cut are overplayed. It still has its believers: JP Morgan is overweight with a target price of 1,550p, only slightly above today’s 1,515p. That confirms my view: forget growth, SSE is all about the income, and the income is good.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Lady wearing a head scarf looks over pages on company financials
Investing Articles

How to try and turn a small ISA into £250k, starting in 2026

With regular contributions and a sound investment strategy, it's possible to turn a small ISA into a huge amount of…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Here’s how much passive income £10,000 worth of Legal & General shares could deliver in 2026

An investment in Legal & General is likely to deliver far more passive income than a high-interest savings account in…

Read more »

Investing Articles

3 potentially explosive penny stocks to consider buying for 2026

Edward Sheldon has scanned the market for penny stocks with significant investment potential as we start 2026. Here are three…

Read more »

Investing Articles

3 top stock market investment ideas for UK investors in 2026

In 2026, the stock market is likely to throw up plenty of lucrative opportunities for investors. Here are three investment…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

How to invest a Stocks and Shares ISA like a pro in 2026

The Stocks and Shares ISA is a powerful investment account. Here are some strategies used by professional investors to get…

Read more »

Investing Articles

£5,000 invested in BP shares could generate this much dividend income in 2026…

Andrew Mackie weighs up whether BP shares’ attractive dividend yield is reason enough for him to keep holding the stock…

Read more »

Investing Articles

In 2026, I think the FTSE 100 could pass 12,000

How could FTSE 100 replicate the success of 2025? Our Foolish author examines why the index might pass 12,000 in…

Read more »

Investing Articles

3 brilliant British shares to consider buying for 2026

If an investor is looking for shares to buy for 2026, they have plenty of great options whether the goal…

Read more »